AltrixBio, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-06-13.
AltrixBio, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on June 13, 2025. The filing reports $6.63M sold. Its industry group is Pharmaceuticals. It names Nancy Briefs (Executive Officer, Director), John Brooks (Director), Jeffrey Karp (Director) (SEC Form D/A, June 13, 2025).
Is this your company?
Sell to companies like AltrixBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns AltrixBio, Inc.
Free to see. No signup.
More on the people and the money behind AltrixBio, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in Massachusetts, filed within 90 days of this one, largest first.
Get an email when AltrixBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when AltrixBio, Inc. raises, hires or launches. No email unless you switch it on.
Watch AltrixBio, Inc. →Get the full cited report on AltrixBio, Inc.
What the filing shows about AltrixBio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on AltrixBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives AltrixBio, Inc.'s address as Corporation Trust Center 1209 Orange St, Wilmington, DE 19801.
Saved here on this device in the meantime, so nothing is lost either way.
Amended on 2025-06-13: the offering size changed from $10,000,000 to $6,632,847; the amount sold changed from $1,150,015 to $6,632,847; the number of investors changed from 20 to 50; proceeds used for payments to executive officers, directors or promoters changed from $75,000 to $0; finders' fees changed from $250,000 to $0. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
AltrixBio, Inc. is a registered filer with the SEC (CIK 2040517) and has filed since 2025-06-13. 3 filings are on record, the latest on 2025-06-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
AltrixBio, Inc.'s Form D of 2025-06-13 names Nancy Briefs, John Brooks, Jeffrey Karp and 1 more as its officers, directors or promoters.
Its new offerings report $2.30M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Nancy Briefs is named as Executive Officer and Director on the Form D that AltrixBio, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
John Brooks is named as Director on the Form D that AltrixBio, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
Jeffrey Karp is named as Director on the Form D that AltrixBio, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
Ali Tavakkoli is named as Director on the Form D that AltrixBio, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2025-06-13 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about AltrixBio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on AltrixBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AltrixBio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist AltrixBio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind AltrixBio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for AltrixBio, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/altrixbio-inc-form-d-25000001